NAFLD in Polycystic Ovary Syndrome: Association with PNPLA3 and Metabolic Features

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorRECUERO, Amanda Medeiros
dc.contributor.authorGOMES, Larissa Garcia
dc.contributor.authorMACIEL, Gustavo Arantes Rosa
dc.contributor.authorMALTA, Fernanda de Mello
dc.contributor.authorSALLES, Ana Paula Moreira
dc.contributor.authorVEZOZZO, Denise Cerqueira Paranagua
dc.contributor.authorBARACAT, Edmund Chada
dc.contributor.authorPINHO, Joao Renato Rebello
dc.contributor.authorCARRILHO, Flair Jose
dc.contributor.authorSTEFANO, Jose Tadeu
dc.contributor.authorOLIVEIRA, Claudia P.
dc.date.accessioned2022-12-21T13:24:30Z
dc.date.available2022-12-21T13:24:30Z
dc.date.issued2022
dc.description.abstractBackground: The aim of this study was to determine the frequency of the rs738409 polymorphism in the patatin-like phospholipase domain containing 3 (PNPLA3) gene in patients with polycystic ovary syndrome (PCOS) and its impact on nonalcoholic fatty liver disease (NAFLD) risk and severity. We also evaluated other risk factors associated with NAFLD and advanced fibrosis. Methods: This was a cross-sectional study involving 163 patients with PCOS at a tertiary center. Genotyping for the PNPLA3 polymorphism was undertaken using a TaqMan assay. The degree of fibrosis was defined by transient elastography. Results: The prevalence of NAFLD was 72.4%, and the polymorphism was heterozygous in 41.7% and homozygous in 8% of patients. Homeostasis model assessment of insulin resistance >= 2.5 was the main factor associated with the risk of developing NAFLD (OR = 4.313, p = 0.022), and its effect was amplified by the polymorphism (OR = 12.198, p = 0.017). Age > 32 years also conferred a higher risk for NAFLD. HDL values >= 50 mg/dL conferred protection against the outcome. Metabolic syndrome (OR = 13.030, p = 0.020) and AST > 32 U/L (OR = 9.039, p = 0.009) were independent risk factors for advanced fibrosis. Conclusions: In women with PCOS, metabolic characteristics are more relevant than PNPLA3 polymorphism regarding the risk for NAFLD and its advanced forms, but these factors can act synergistically, increasing disease risk.eng
dc.description.indexPubMedeng
dc.identifier.citationBIOMEDICINES, v.10, n.11, article ID 2719, 12p, 2022
dc.identifier.doi10.3390/biomedicines10112719
dc.identifier.eissn2227-9059
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50595
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofBiomedicines
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectNAFLDeng
dc.subjectPCOSeng
dc.subjectinsulin resistanceeng
dc.subjectpatatin-like phospholipase domain containing 3eng
dc.subject.otherfatty liver-diseaseeng
dc.subject.otherinsulin-resistanceeng
dc.subject.otheramerican associationeng
dc.subject.otherdiagnostic-criteriaeng
dc.subject.othermanagementeng
dc.subject.otherwomeneng
dc.subject.otherfibrosiseng
dc.subject.othercollegeeng
dc.subject.otheracideng
dc.subject.wosBiochemistry & Molecular Biologyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleNAFLD in Polycystic Ovary Syndrome: Association with PNPLA3 and Metabolic Featureseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus2
hcfmusp.contributor.author-fmusphcAMANDA MEDEIROS RECUERO
hcfmusp.contributor.author-fmusphcLARISSA GARCIA GOMES
hcfmusp.contributor.author-fmusphcGUSTAVO ARANTES ROSA MACIEL
hcfmusp.contributor.author-fmusphcFERNANDA DE MELLO MALTA
hcfmusp.contributor.author-fmusphcANA PAULA MOREIRA SALLES
hcfmusp.contributor.author-fmusphcDENISE CERQUEIRA PARANAGUA VEZOZZO
hcfmusp.contributor.author-fmusphcEDMUND CHADA BARACAT
hcfmusp.contributor.author-fmusphcJOAO RENATO REBELLO PINHO
hcfmusp.contributor.author-fmusphcFLAIR JOSE CARRILHO
hcfmusp.contributor.author-fmusphcJOSE TADEU STEFANO
hcfmusp.contributor.author-fmusphcCLAUDIA PINTO MARQUES SOUZA DE OLIVEIRA
hcfmusp.description.articlenumber2719
hcfmusp.description.issue11
hcfmusp.description.volume10
hcfmusp.origemWOS
hcfmusp.origem.pubmed36359239
hcfmusp.origem.scopus2-s2.0-85141809815
hcfmusp.origem.wosWOS:000881000600001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAngulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496eng
hcfmusp.relation.referenceArmandi A, 2021, METABOLITES, V11, DOI 10.3390/metabo11030155eng
hcfmusp.relation.referenceAzziz R, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.57eng
hcfmusp.relation.referenceBrzozowska MM, 2009, J GASTROEN HEPATOL, V24, P243, DOI 10.1111/j.1440-1746.2008.05740.xeng
hcfmusp.relation.referenceChalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001eng
hcfmusp.relation.referenceChang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004eng
hcfmusp.relation.referenceCotter TG, 2020, GASTROENTEROLOGY, V158, P1851, DOI 10.1053/j.gastro.2020.01.052eng
hcfmusp.relation.referencede Ledinghen V, 2010, EXPERT REV MED DEVIC, V7, P811, DOI [10.1586/erd.10.46, 10.1586/ERD.10.46]eng
hcfmusp.relation.referenceDokras A, 2017, FERTIL STERIL, V107, P1380, DOI 10.1016/j.fertnstert.2017.04.011eng
hcfmusp.relation.referenceFalcetta P, 2021, J ENDOCRINOL INVEST, V44, P2725, DOI 10.1007/s40618-021-01594-5eng
hcfmusp.relation.referenceGrundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404eng
hcfmusp.relation.referenceHandelsman Y, 2015, ENDOCR PRACT, V21, P1, DOI [10.4158/EP15672.GLSUPPL, 10.4158/EP15672.GL]eng
hcfmusp.relation.referenceHossain N, 2011, SCAND J GASTROENTERO, V46, P479, DOI 10.3109/00365521.2010.539251eng
hcfmusp.relation.referenceHuang C, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2020.08.006eng
hcfmusp.relation.referenceKanwar P, 2016, BMJ OPEN GASTROENTER, V3, DOI 10.1136/bmjgast-2016-000114eng
hcfmusp.relation.referenceLegro RS, 2013, J CLIN ENDOCR METAB, V98, P4565, DOI 10.1210/jc.2013-2350eng
hcfmusp.relation.referenceMaciejewska D, 2015, WORLD J GASTROENTERO, V21, P301, DOI 10.3748/wjg.v21.i1.301eng
hcfmusp.relation.referenceMacut D, 2016, HUM REPROD, V31, P1347, DOI 10.1093/humrep/dew076eng
hcfmusp.relation.referenceMacut D, 2017, EUR J ENDOCRINOL, V177, pR145, DOI 10.1530/EJE-16-1063eng
hcfmusp.relation.referenceMalgorzata S, 2017, PROSTAG LEUKOTR ESS, V126, P105, DOI 10.1016/j.plefa.2017.09.001eng
hcfmusp.relation.referenceMATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883eng
hcfmusp.relation.referenceOliveira AIN, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01654-3eng
hcfmusp.relation.referencePaschou SA, 2020, ENDOCRINE, V67, P1, DOI 10.1007/s12020-019-02085-7eng
hcfmusp.relation.referenceRamezani-Binabaj M, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.23235eng
hcfmusp.relation.referenceRocha ALL, 2017, J ENDOCRINOL INVEST, V40, P1279, DOI 10.1007/s40618-017-0708-9eng
hcfmusp.relation.referenceRomeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257eng
hcfmusp.relation.referenceSasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005eng
hcfmusp.relation.referenceSetji TL, 2006, J CLIN ENDOCR METAB, V91, P1741, DOI 10.1210/jc.2005-2774eng
hcfmusp.relation.referenceSookoian S, 2009, J LIPID RES, V50, P2111, DOI 10.1194/jlr.P900013-JLR200eng
hcfmusp.relation.referenceStender S, 2017, NAT GENET, V49, P842, DOI 10.1038/ng.3855eng
hcfmusp.relation.referenceSterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178eng
hcfmusp.relation.referenceTai CM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003120eng
hcfmusp.relation.referenceTeede HJ, 2018, FERTIL STERIL, V110, P364, DOI 10.1016/j.fertnstert.2018.05.004eng
hcfmusp.relation.referenceTrojak A, 2013, MED SCI MONITOR, V19, P1167, DOI 10.12659/MSM.889649eng
hcfmusp.relation.referenceVasques ACJ, 2008, ARQ BRAS ENDOCRINOL, V52, P32, DOI 10.1590/S0004-27302008000100006eng
hcfmusp.relation.referenceWang JZ, 2018, WORLD J CLIN CASES, V6, P167, DOI 10.12998/wjcc.v6.i8.167eng
hcfmusp.relation.referenceWhelton PK, 2018, J AM COLL CARDIOL, V71, P2275, DOI 10.1016/j.jacc.2018.03.016eng
hcfmusp.relation.referenceWHO Consultation, 2000, WHO TECH REP SER, V894, P1eng
hcfmusp.relation.referenceWong GLH, 2013, CLIN GASTROENTEROL H, V11, P295, DOI 10.1016/j.cgh.2012.09.025eng
hcfmusp.relation.referenceWong VWS, 2019, GUT, V68, P2057, DOI 10.1136/gutjnl-2018-317334eng
hcfmusp.relation.referenceYounossi ZM, 2019, J HEPATOL, V71, P793, DOI 10.1016/j.jhep.2019.06.021eng
hcfmusp.relation.referenceZhang JH, 2018, EXP THER MED, V15, P4259, DOI 10.3892/etm.2018.5932eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationf95412a3-886a-465f-8be9-2e7d32d62276
relation.isAuthorOfPublication2ac9152d-5aba-4f4d-83ef-29c289fcf345
relation.isAuthorOfPublicatione4903b44-676f-49fc-a298-4c8256b8d0e3
relation.isAuthorOfPublicationa9324386-13b6-4aae-8f0c-8273588275c3
relation.isAuthorOfPublicationdc8dbc8b-1a69-487b-b5f5-2d0cda8953a1
relation.isAuthorOfPublication58f433fb-b05a-4a3b-a012-7c448d860398
relation.isAuthorOfPublication27af1fa4-ab33-4cdc-b80d-16dd66b6ac76
relation.isAuthorOfPublication0ada2eb1-5ac2-4e40-b4e2-6af14f33268b
relation.isAuthorOfPublication9221b8d6-ad80-46e5-a56f-fb3b28a8c155
relation.isAuthorOfPublication81ce20f6-5571-4ba5-838a-b5cc84182225
relation.isAuthorOfPublication6fe5bca4-b5ef-47da-b77a-5e60d87e165f
relation.isAuthorOfPublication.latestForDiscoveryf95412a3-886a-465f-8be9-2e7d32d62276
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_RECUERO_NAFLD_in_Polycystic_Ovary_Syndrome_Association_with_PNPLA3_2022.PDF
Tamanho:
610.16 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/42
Artigos e Materiais de Revistas Científicas - LIM/58